• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Ranbaxy Ends Drug Discovery Pact With Merck

      Posted Atonline.wsj.com

      BANGALORE -- Ranbaxy Laboratories Ltd. has discontinued a drug discovery and clinical development collaboration with Merck & Co. Inc. aimed at developing new Anti-Bacterial and anti-fungal drugs, a spokesman for the Indian drug maker said Thursday.

      He didn't elaborate.

      In May 2008 Ranbaxy and Merck entered an agreement for the joint development of the drugs and the collaboration was initially for five years.

      Ranbaxy was to receive an undisclosed up-front sum, with the potential to receive payments totaling more than $100 million associated with the achievement of various research, development and regulatory milestones for each target included in the collaboration.

      Ranbaxy was also eligible to receive significant royalties on worldwide net sales of any products commercialized under the agreement.

      Jan 25, 2011


       

      Share this Article!

    Back to top^